Trending
- Rovadicitinib, a first-in-class JAK/ROCK inhibitor, in patients with myelofibrosis: a preclinical and phase I study
- How to Suffer Less When You’re Waiting for Answers
- Evolving Frontline Management in Newly Diagnosed Multiple Myeloma
- Checkpoint Inhibitor Evidence: EMPOWER and C-POST Trials
- Daratumumab-Based Frontline Therapy in Newly Diagnosed Multiple Myeloma
- Obesity and Cancer Risk: The Evolving Role of GLP-1s in Oncology
- Ebola and hantavirus can start like the flu but turn deadly fast
- A common vitamin could help fight one of the deadliest brain cancers
